Immune checkpoint therapy—current perspectives and future directions
P Sharma, S Goswami, D Raychaudhuri, BA Siddiqui… - Cell, 2023 - cell.com
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …
patients and conferred durable clinical benefits, including cure in a subset of patients …
[HTML][HTML] Exploring immunotherapy in colorectal cancer
J Weng, S Li, Z Zhu, Q Liu, R Zhang, Y Yang… - Journal of hematology & …, 2022 - Springer
Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
[PDF][PDF] Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution
Tumor evolution is driven by the progressive acquisition of genetic and epigenetic
alterations that enable uncontrolled growth and expansion to neighboring and distal tissues …
alterations that enable uncontrolled growth and expansion to neighboring and distal tissues …
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
KRAS is the most frequently mutated oncogene, harboring mutations in approximately one
in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment …
in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment …
[HTML][HTML] Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
Introduction STK11 and KEAP1 mutations (STK11 mutant [STK11 MUT] and KEAP1 MUT)
are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 …
are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 …
Metabolic reprogramming and cancer progression
BACKGROUND Metabolic reprogramming is a hallmark of malignancy first recognized a
century ago. In some cases, reprogrammed metabolic activities can be exploited to …
century ago. In some cases, reprogrammed metabolic activities can be exploited to …
The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease
Abstract The Ser/Thr kinase mechanistic target of rapamycin (mTOR) is a central regulator of
cellular metabolism. As part of mTOR complex 1 (mTORC1), mTOR integrates signals such …
cellular metabolism. As part of mTOR complex 1 (mTORC1), mTOR integrates signals such …
[HTML][HTML] Targeting KRAS mutant cancers: from druggable therapy to drug resistance
C Zhu, X Guan, X Zhang, X Luan, Z Song, X Cheng… - Molecular Cancer, 2022 - Springer
Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
F Skoulidis, JV Heymach - Nature Reviews Cancer, 2019 - nature.com
The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
[HTML][HTML] Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Background Sotorasib showed anticancer activity in patients with KRAS p. G12C–mutated
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …